drugset / Trial / NCT06497049

Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221 (GEROPHARM LLC, Russia) and Ozempic®.

NCT06497049

Phase 1 Completed 120 enrolled Geropharm
RandomizedParallel-groupOpen-labelTreatment

Summary

Study of comparative pharmacokinetics and biosimilarity of drugs containing semaglutide - GP40221 and Ozempic® in healthy volunteers.

Timeline

Start
2023-06-30
Primary completion
2024-05-05
Completion
2024-05-05

Drugs

EvaluationDrugModalityDoseRoute
Subject GP40221 Unknown 0.5 mg Subcutaneous
Comparator Semaglutide Peptide 0.5 mg Subcutaneous

Indications

No indication recorded.